S-cholesteryl-thio acetate | 1443-86-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: S-cholesteryl-thio acetate
• 英文别名: 3β-Acetylthio-cholesten-(5)；S-cholesteryl-thio acetate；S-Cholesteryl-thioacetat；3β-Acetylmercapto-cholesten-(5)；Thioessigsaeure-S-cholesterylester
• CAS: 1443-86-3
• 化学式: C₂₉H₄₈OS
• 分子量: 444.766
• InChiKey: UFPPGUCEMBPCTH-VEVYEIKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.68
• 重原子数：
  31.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.07
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  S-cholesteryl-thio acetate 、 alkaline earth salt of/the/ methylsulfuric acid 在 dicholesteryl disulfide 作用下， 生成 dicholesteryl trisulfide
  参考文献：
  名称：

  Hemodialysis vascular access survival: Upper-arm native arteriovenous fistula

  摘要：

  Achieving Dialysis Outcomes Quality Initiative guidelines for native arteriovenous fistulae using the radiocephalic forearm fistula (lower-arm fistula [LAF]) is difficult. This study reports results using the upper-arm native arteriovenous fistula (UAF). From a prospective access database (1992 to 1998), this study was based on 204 patients (322 accesses). Average patient age was 56 +/- 1 years, 63% were men, and 47% had diabetes. A native fistula was the first access in 73% of patients (36%, LAFs; 37%, UAFs) and accounted for 48% of subsequent accesses (13%, LAFs; 35%, UAFs). Younger men were more likely to receive an LAF, but there was no demographic difference between patients receiving a UAF or arteriovenous graft (AVG). Both primary unassisted and cumulative access patencies were significantly better for UAFs than either LAFs or AVGs. For first accesses, cumulative access patency rates at 1, 3, and 5 years were 71%, 57%, and 57% for UAFs; 54%, 46%, and 36% for LAFs; and 54%, 28%, and 0% for AVGs (P < 0.01). Despite shorter access survival, AVGs required more total access procedures than either UAFs or LAFs (procedures per access: 2.5, 1.0, and 0.6 for AVGs, UAFs, and LAFs, respectively). When used, catheters were required for dialysis for a longer time for UAFs (median catheter days, 36, 53, and 56 for AVGs, LAFs, and UAFs, respectively; P < 0.05). Access flow rates were greater in UAFs (1,247 mL/min; n = 48; P < 0.01) than AVGs (851 mL/min; n = 30) or LAFs (938 mL/min; n = 31). There was no evidence that UAFs were banded or ligated for steal syndromes or heart failure more often than AVGs or LAFs. These results show that the UAF Is a good alternative to an AVG for achieving Dialysis Outcomes Quality Initiative guidelines. (C) 2002 by the National Kidney Foundation, Inc.

  DOI：

  10.1053/ajkd.2002.29886
• 作为产物：
  描述：

  amino-[[[(3S,8S,9S,10R,13R,14S,17R)-3-bromo-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]hydrothio]methylidene]ammonium bromide 在 哌啶 、 sodium sulfide 、 乙醇 作用下， 生成 S-cholesteryl-thio acetate
  参考文献：
  名称：

  US2375873

  摘要：

  公开号：

文献信息

• Δ^{5, 7}-STEROIDS. V. (1). 7-DEHYDROCHOLESTERYL MERCAPTAN
  作者：SEYMOUR BERNSTEIN、KARL J. SAX

  DOI：10.1021/jo01145a004

  日期：1951.5